Stay updated on BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial

Sign up to get notified when there's something new on the BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the pharmacokinetics, pharmacodynamics, efficacy, or safety data of BCD-020 (rituximab) in comparison with MabThera in the treatment of indolent non-Hodgkin's lymphoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:28:51.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as age, health conditions, and prior treatments for CD20-positive indolent non-Hodgkin lymphoma. Previously, this section indicated that no information was provided.
    Difference
    27%
    Check dated 2024-05-22T21:11:03.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:19:17.000Z thumbnail image

Stay in the know with updates to BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial page.